| abstract |
The present invention provides an immunogenic analogue of human TNFα protein, the analogue comprising an immunogenized monomer TNFα polypeptide or TNFα dimer or trimer, and also reducing toxicity or avoiding toxicity selected from Y87S, D143N or A145R. In addition to mutations, the amino acid numbering is from the N-terminal valine of human TNFα. The present invention also provides nucleic acid fragments encoding the analogs and vectors and transformed cells useful for preparing the analogs. Also disclosed is a method of down-regulating TNFα in a subject in need of downregulation of TNFα. |